Updates are available Correction dated 2021-01-19
Click to view Correction: https://doi.org/10.1038/s41586-020-03102-w
-
Authors
Sahin, Ugur https://orcid.org/0000-0003-0363-1564
Muik, Alexander https://orcid.org/0000-0003-4561-2273
Derhovanessian, Evelyna
Vogler, Isabel https://orcid.org/0000-0001-9757-9618
Kranz, Lena M.
Vormehr, Mathias https://orcid.org/0000-0001-7788-3380
Baum, Alina
Pascal, Kristen https://orcid.org/0000-0003-4826-4606
Quandt, Jasmin https://orcid.org/0000-0001-9589-9941
Maurus, Daniel
Brachtendorf, Sebastian
Lörks, Verena
Sikorski, Julian
Hilker, Rolf https://orcid.org/0000-0002-8576-7731
Becker, Dirk
Eller, Ann-Kathrin
Grützner, Jan
Boesler, Carsten
Rosenbaum, Corinna
Kühnle, Marie-Cristine
Luxemburger, Ulrich
Kemmer-Brück, Alexandra
Langer, David
Bexon, Martin https://orcid.org/0000-0002-5361-4343
Bolte, Stefanie
Karikó, Katalin https://orcid.org/0000-0002-1864-3851
Palanche, Tania
Fischer, Boris
Schultz, Armin
Shi, Pei-Yong https://orcid.org/0000-0001-5553-1616
Fontes-Garfias, Camila
Perez, John L.
Swanson, Kena A. https://orcid.org/0000-0002-3389-8414
Loschko, Jakob
Scully, Ingrid L.
Cutler, Mark
Kalina, Warren
Kyratsous, Christos A.
Cooper, David
Dormitzer, Philip R.
Jansen, Kathrin U.
Türeci, Özlem
- License Information
-
More Information
Article History
Received: 16 July 2020
Accepted: 22 September 2020
First Online: 30 September 2020
Change Date: 19 January 2021
Change Type: Correction
Change Details: A Correction to this paper has been published: https://doi.org/10.1038/s41586-020-03102-w
Competing interests
: All authors have completed the International Committee of Medical Journal Editors (ICMJE) uniform disclosure form at https://www.gisaid.orgwww.icmje.org/coi_disclosure.pdf` and declare: U.S. and Ö.T. are management board members and employees at BioNTech SE (Mainz, Germany); D.B., C.B., S. Brachtendorf, E.D., A.-K.E., B.F., J.G., R.H., M.-C.K., U.L., V.L., D.M., C.R., J.S. and T.P. are employees at BioNTech SE; K.K., L.M.K., I.V., A.M., J.Q. and M.V. are employees at BioNTech RNA Pharmaceuticals GmbH; M.B. is an employee at Bexon Clinical Consulting LLC. A.B., C.A.K. and K.P. are employees of Regeneron Pharmaceuticals Inc; K.K., A.M., U.S. and Ö.T. are inventors on patents and patent applications related to RNA technology and COVID-19 vaccine; D.B., C.B., S. Bolte, E.D., J.G., K.K., R.H., A.K.-B., L.M.K., D.L., U.L., A.M., C.R., U.S., Ö.T., I.V. and M.V. have securities from BioNTech SE; D.C., M.C., P.R.D., K.U.J., W.K., J.L., J.L.P., I.L.S. and K.A.S. are employees at Pfizer and may have securities from Pfizer; C.A.K. is an officer at Regeneron Pharmaceuticals, Inc; A.B., C.A.K. and K.P. have securities from Regeneron Pharmaceuticals, Inc; C.F.-G. and P.-Y.S. received compensation from Pfizer to perform the neutralization assay; no other relationships or activities that could appear to have influenced the submitted work.
Free to read: This content has been made available to all.
